KIA
CDMO

Kraematon Investment Advisors’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Kraematon Investment Advisors’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-358
Closed -$4.93K – 263
2022
Q4 		$4.93K Buy
+358
New +$5.48K 0.01% 226

Other funds holding CDMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Kraematon Investment Advisors's CDMO Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2023, closing a stake of 358 shares — an estimated $4.93K sold.

Kraematon Investment Advisors first reported a position in CDMO in Q4 2022 and held it in 1 quarter. The position peaked at $4.93K in Q4 2022. 168 funds tracked by Wall St. Rank hold CDMO as of Q1 2023.

  • Kraematon Investment Advisors reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Kraematon Investment Advisors sold 358 Avid Bioservices, Inc. Common Stock shares in Q1 2023, an estimated $4.93K.
  • Kraematon Investment Advisors first reported a position in Avid Bioservices, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Kraematon Investment Advisors's Avid Bioservices, Inc. Common Stock position peaked at $4.93K in Q4 2022.
  • 168 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.